{"id":809369,"date":"2025-02-05T16:20:32","date_gmt":"2025-02-05T21:20:32","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/rani-therapeutics-announces-preclinical-data-demonstrating-successful-oral-delivery-of-semaglutide-via-ranipill-hc\/"},"modified":"2025-02-05T16:20:32","modified_gmt":"2025-02-05T21:20:32","slug":"rani-therapeutics-announces-preclinical-data-demonstrating-successful-oral-delivery-of-semaglutide-via-ranipill-hc","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/rani-therapeutics-announces-preclinical-data-demonstrating-successful-oral-delivery-of-semaglutide-via-ranipill-hc\/","title":{"rendered":"Rani Therapeutics Announces Preclinical Data Demonstrating Successful Oral Delivery of Semaglutide via RaniPill\u00ae HC"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <em>&#8211; Oral semaglutide administered via the RaniPill\u00ae HC (RT-116) demonstrated comparable bioavailability, pharmacokinetics and weight loss to subcutaneous administration &#8211;<\/em>\n      <\/p>\n<p align=\"center\">\n        <em>&#8211; RT-116 was well tolerated with no serious adverse events &#8211;<\/em>\n      <\/p>\n<p align=\"center\">\n        <em>&#8211; Data adds to growing body of evidence of the RaniPill<sup>\u00ae<\/sup> platform\u2019s potential to enable oral delivery of multiple obesity treatments &#8211;<\/em>\n      <\/p>\n<p align=\"center\">\n        <em>&#8211; Phase 1 study for RT-114, an oral GLP-1\/GLP-2 dual agonist for the treatment of obesity, expected to initiate in 2025 &#8211;<\/em>\n      <\/p>\n<p align=\"justify\">SAN JOSE, Calif., Feb.  05, 2025  (GLOBE NEWSWIRE) &#8212; Rani Therapeutics Holdings, Inc. (\u201cRani Therapeutics\u201d or \u201cRani\u201d) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced new pharmacokinetic and pharmacodynamic data from a preclinical study evaluating the oral delivery of the glucagon-like peptide-1 receptor (GLP-1) agonist semaglutide administered via the RaniPill<sup>\u00ae<\/sup> capsule.<\/p>\n<p align=\"justify\">Semaglutide is a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor mimicking its activity. GLP-1\u00a0is an incretin hormone and enterogastrone that stimulates insulin secretion, inhibits glucagon secretion, delays gastric emptying and reduces the production of stomach acid serving as a physiological regulator of appetite and food intake.<\/p>\n<p align=\"justify\">\u201cWe believe these data provide further validation of the RaniPill<sup>\u00ae<\/sup> oral delivery platform across a wide variety of injectable obesity treatments. We are encouraged to see that delivery of semaglutide via the RaniPill<sup>\u00ae<\/sup> capsule demonstrated comparable bioavailability, pharmacokinetics and weight loss to subcutaneous administration of semaglutide at the same dose,\u201d said Talat Imran, Chief Executive Officer of Rani Therapeutics. \u201cThe target product profile of semaglutide in the RaniPill<sup>\u00ae<\/sup> capsule would be once-weekly oral administration of semaglutide therapy, which we believe may be more convenient for patients and could lead to improved adherence. Overall, the totality of the preclinical data we have generated in the obesity space demonstrating the successful delivery of both single and triagonist incretin therapies gives us confidence to continue building our obesity portfolio to unlock the true value of the RaniPill<sup>\u00ae<\/sup> technology. Looking ahead, we are excited to begin our Phase 1 study for RT-114, Rani\u2019s GLP-1\/GLP-2 dual agonist in partnership with ProGen this year.\u201d<\/p>\n<p align=\"justify\">Currently, semaglutide is only available as a subcutaneous injection (SC) for the treatment of obesity and is marketed in the U.S. by Novo Nordisk as WEGOVY<sup>\u00ae<\/sup>. Worldwide sales for WEGOVY<sup>\u00ae<\/sup> were approximately $3.1 billion in the first half of 2024.<\/p>\n<p align=\"justify\">\u201cThere are currently no approved orally-administered GLP-1 agonists on the market for the treatment of obesity,\u201d said Jesper H\u00f8iland, Senior Strategic Advisor for Rani Therapeutics and former executive at Novo Nordisk. \u201cWhile RYBELSUS<sup>\u00ae<\/sup> is an oral version of semaglutide approved to improve glycemic control in adults with type 2 diabetes mellitus, it requires daily administration at a significantly higher dose than the subcutaneous equivalent. In comparison, the RaniPill HC harnesses advanced technology to deliver the same dose as the subcutaneous injection of semaglutide with expected weekly oral administration. I believe that a convenient, once-weekly oral version of semaglutide delivered via the RaniPill HC has the potential to be transformational as a next generation treatment that would impact how obesity is treated worldwide.\u201d<\/p>\n<p align=\"justify\">\n        <strong>Study Design<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">The nonclinical pharmacokinetic (PK) and pharmacodynamic (PD) study was conducted to examine the effects of semaglutide delivered orally via the RaniPill (RT-116) versus a subcutaneous (SC) injection comparator group.<\/li>\n<li style=\"text-align:justify\">The 2&#215;2 crossover study was conducted in two parts with a period of 4 weeks separating the two groups to evaluate the PK, PD and safety of RT-116.<\/li>\n<li style=\"text-align:justify\">Eight canines were randomized into two groups who received 0.5mg of semaglutide delivered via oral administration of the RaniPill<sup>\u00ae<\/sup> HC (N=4) or subcutaneous injection (N=4).<\/li>\n<li style=\"text-align:justify\">Endpoints included plasma drug concentrations, body weight, food intake, lipid profile, and safety.<\/li>\n<\/ul>\n<p align=\"justify\">\n        <strong>Data Highlights<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">Semaglutide was successfully delivered in 7 of 8 canines that received the RaniPill<sup>\u00ae<\/sup> capsule.<\/li>\n<li style=\"text-align:justify\">Semaglutide administered via the RaniPill<sup>\u00ae<\/sup> capsule was well tolerated with no serious adverse events.<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">C<sub>max<\/sub>, T<sub>max<\/sub>, and AUC were comparable for semglutide administered via RaniPill<sup>\u00ae<\/sup> capsule and subcutaneous administration of semaglutide.<\/li>\n<li style=\"text-align:justify\">Oral administration via the RaniPill<sup>\u00ae<\/sup> capsule demonstrated bioavailability and biological activity comparable to subcutaneous administration.<\/li>\n<li style=\"text-align:justify\">The relative bioavailability of oral semaglutide was 107% versus subcutaneous administration.<\/li>\n<li style=\"text-align:justify\">Both groups saw comparable weight loss which appeared to be driven by decreased food intake that coincided with rises in plasma drug levels thus indicating there is a PD effect to treatment.<\/li>\n<li style=\"text-align:justify\">Both groups saw comparable moderate decreases in serum triglycerides and cholesterol.<\/li>\n<\/ul>\n<p \/>\n<p>\n        \n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:20%;width:20%;min-width:20%;vertical-align: middle;text-align: left;padding-left: 10.0px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>Route<\/strong>\n          <\/td>\n<td style=\"max-width:20%;width:20%;min-width:20%;vertical-align: middle;text-align: left;padding-left: 10.0px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">\n            <strong>C<\/strong><br \/>\n            <sub><br \/>\n              <strong>max<\/strong><br \/>\n            <\/sub><br \/>\n            <br \/>\n            <strong>(ng\/mL)<\/strong>\n          <\/td>\n<td style=\"max-width:20%;width:20%;min-width:20%;vertical-align: middle;text-align: left;padding-left: 10.0px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">\n            <strong>T<\/strong><br \/>\n            <sub><br \/>\n              <strong>max<\/strong><br \/>\n            <\/sub><br \/>\n            <br \/>\n            <strong>(days)<\/strong>\n          <\/td>\n<td style=\"max-width:20%;width:20%;min-width:20%;vertical-align: middle;text-align: left;padding-left: 10.0px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">\n            <strong>T<\/strong><br \/>\n            <sub><br \/>\n              <strong>last<\/strong><br \/>\n            <\/sub><br \/>\n            <br \/>\n            <strong>(days)<\/strong>\n          <\/td>\n<td style=\"max-width:20%;width:20%;min-width:20%;vertical-align: middle;text-align: left;padding-left: 10.0px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">\n            <strong>AUC<\/strong><br \/>\n            <sub><br \/>\n              <strong>last<\/strong><br \/>\n            <\/sub><br \/>\n            <br \/>\n            <strong>(ng\/mL*day)<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 10.0px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Oral (RT-116)<\/td>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 10.0px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">941 \u00b1 90<\/td>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 10.0px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">1.3 \u00b1 0.3<\/td>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 10.0px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">17 \u00b1 2<\/td>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 10.0px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">3630 \u00b1 222<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 10.0px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">SC<\/td>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 10.0px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">948 \u00b1 120<\/td>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 10.0px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">1.3 \u00b1 0.3<\/td>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 10.0px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">17 \u00b1 1<\/td>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 10.0px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">3390 \u00b1 402<\/td>\n<\/tr>\n<tr>\n<td colspan=\"5\" style=\"vertical-align: middle;text-align: left;padding-left: 10.0px;border-top: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">All data is mean \u00b1 standard error.<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\" \/>\n<p align=\"justify\">\n        <strong>Near-Term Milestone Expectations:<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">Initiation of Phase 1 clinical trial of RT-114 containing a GLP-1\/GLP-2 dual agonist for the treatment of obesity expected in 2025.<\/li>\n<\/ul>\n<p align=\"justify\">\n        <strong>About Rani Therapeutics<\/strong><br \/>\n        <br \/>Rani Therapeutics is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. Rani has developed the RaniPill<sup>\u00ae<\/sup> capsule, which is a novel, proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. Rani has successfully conducted several preclinical and clinical studies to evaluate safety, tolerability and bioavailability using RaniPill<sup>\u00ae<\/sup> capsule technology. For more information, visit ranitherapeutics.com.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements <\/strong><br \/>\n        <br \/>Statements contained in this press release regarding matters that are not historical facts are \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, the expected initiation of a Phase 1 trial of RT-114 in 2025, the potential of the RaniPill<sup>\u00ae<\/sup> platform to enable oral delivery of multiple obesity treatments and validation of such potential through preclinical data, the target product profile of semaglutide delivered via the RaniPill<sup>\u00ae<\/sup> capsule, the novelty, convenience and attractiveness of a once-weekly oral semaglutide treatment for patients, Rani\u2019s confidence to continue building an obesity portfolio, the potential of a once-weekly oral version of semaglutide in the RaniPill<sup>\u00ae<\/sup> capsule to deliver the same benefits as subcutaneous delivery and to impact patients\u2019 lives, the sufficiency of Rani\u2019s cash reserves, and future financial performance. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as \u201cbelieve,\u201d \u201cwould,\u201d \u201cpotential,\u201d \u201cexpect,\u201d \u201ccontinue\u201d and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Rani\u2019s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with Rani\u2019s business in general and the other risks described in Rani\u2019s filings with the Securities and Exchange Commission, including Rani\u2019s annual report on Form 10-K for the year ended December 31, 2023, and subsequent filings and reports by Rani. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management\u2019s assumptions and estimates as of such date. Rani undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.<\/p>\n<p align=\"justify\">\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=S7BHcS_YH1Wqg74lVhNPAPhHR0GdHTDysvQOCHCEAaMa10ItKvr0n0HjQ7zcruveylpLg7wFS0H__wxh-kv3Fmstsx3N4k9ZHnuDME_-AifxhwDSmqy6IFKPoeX_E7MS\" rel=\"nofollow\" target=\"_blank\">investors@ranitherapeutics.com<\/a>\n      <\/p>\n<p align=\"justify\">\n        <strong>Media Contact:<\/strong><br \/>\n        <br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=omJDx0pElNPpgTeRVtP68ptwuIWPGVWzPNcep59F-C-nsnIT56LQyGploMVYM4D6EQhmq6iR53daORFA81fktp2kvy23JE87ivo5oRIhkhFVPkVrXO7aebjXpqV9jjbK\" rel=\"nofollow\" target=\"_blank\">media@ranitherapeutics.com<\/a>\n      <\/p>\n<p>Photos accompanying this announcement are available at:<\/p>\n<p>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-rPXVxUYyU02xDMRnH1KntyXS2SP04ouAmKRElVOSLp_DVh3F3sA1RFzA9Xq72tm534-8JA-ttMb7jNHqOg2dMyxqSKgxYaVgt1wi15hFKSf0f272HrQrlE3_XombrrFo1B2XxQED0sFxQSBoEw5uB7A1trMCZP-M2BhurSjx1GNRuEWbQ-TZKQsnZ8vMOJZ9DzWhQB66ueybIhqk3Fin4qLWwGZb3FNIzQLBA3EHqmpI-35fktTYnXY8mWPpLurp3JXU6kjPVQWfyKhk_Uydw==\" rel=\"nofollow\" target=\"_blank\">https:\/\/www.globenewswire.com\/NewsRoom\/AttachmentNg\/b1fecb62-a30c-4b59-9234-245cebe4e59e<\/a>\n      <\/p>\n<p>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-rPXVxUYyU02xDMRnH1KntyXS2SP04ouAmKRElVOSLp_DVh3F3sA1RFzA9Xq72tmdOuPm1izWbn_y_jrXx8IP0bpdiPZU_8YycOGymQJHh5weo6jCgAtadg8VV_3GmJ3edhlTNaBAVxCVrX6m3DhGeIMzGMzyObxAOQM_46yV3tyoAs9dRK_orcYoytiMVKZBPmqP9Nl3xmucQun1Y8utIpndxhCu_Kkonjasb1e1Zvaoy3QzS3ION0rk0kOFbjMsPGgWpDxbslLkqnGpjPnbw==\" rel=\"nofollow\" target=\"_blank\">https:\/\/www.globenewswire.com\/NewsRoom\/AttachmentNg\/d32ef495-95db-41e6-8429-a597576d5ed1<\/a>\n      <\/p>\n<p align=\"justify\">An attachment\u00a0accompanying this announcement is available at:\u00a0<\/p>\n<p align=\"justify\">\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-rPXVxUYyU02xDMRnH1KntyXS2SP04ouAmKRElVOSLp_DVh3F3sA1RFzA9Xq72tmRV-BSaQQOEaUtvCmlQVuD7txLl76llIXiwwicb0vG_e2I7jrxC58ACJ6-OhugjuRavSdYf6miKpniO4HSTzcrjL60SabRMpzsbYyCij4bcQH2sLgyjzkTY9RND8v381NwF_-g72aPevBY25XFM98SET7KmDwxuutA_oJ4dLUHVhPbyWFD5ERMzt8aJh5Saqv5mWpSiI3IpqCbNqjagQwDQ==\" rel=\"nofollow\" target=\"_blank\">https:\/\/www.globenewswire.com\/NewsRoom\/AttachmentNg\/61c2f390-a3c5-45ab-901e-37f49f6ab4f2<\/a>\n      <\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1MzgyMCM2NzM3NjQ3IzIyMDg2OTk=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MjdjZWM4ZTMtZmJiNC00ODI0LWE4MDctZjViM2ZjZDNjNmY5LTEyMjAyNTI=\/tiny\/Rani-Therapeutics-LLC.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>&#8211; Oral semaglutide administered via the RaniPill\u00ae HC (RT-116) demonstrated comparable bioavailability, pharmacokinetics and weight loss to subcutaneous administration &#8211; &#8211; RT-116 was well tolerated with no serious adverse events &#8211; &#8211; Data adds to growing body of evidence of the RaniPill\u00ae platform\u2019s potential to enable oral delivery of multiple obesity treatments &#8211; &#8211; Phase 1 study for RT-114, an oral GLP-1\/GLP-2 dual agonist for the treatment of obesity, expected to initiate in 2025 &#8211; SAN JOSE, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) &#8212; Rani Therapeutics Holdings, Inc. (\u201cRani Therapeutics\u201d or \u201cRani\u201d) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced new pharmacokinetic and pharmacodynamic data from a preclinical study evaluating the &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/rani-therapeutics-announces-preclinical-data-demonstrating-successful-oral-delivery-of-semaglutide-via-ranipill-hc\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Rani Therapeutics Announces Preclinical Data Demonstrating Successful Oral Delivery of Semaglutide via RaniPill\u00ae HC&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-809369","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Rani Therapeutics Announces Preclinical Data Demonstrating Successful Oral Delivery of Semaglutide via RaniPill\u00ae HC - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/rani-therapeutics-announces-preclinical-data-demonstrating-successful-oral-delivery-of-semaglutide-via-ranipill-hc\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Rani Therapeutics Announces Preclinical Data Demonstrating Successful Oral Delivery of Semaglutide via RaniPill\u00ae HC - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"&#8211; Oral semaglutide administered via the RaniPill\u00ae HC (RT-116) demonstrated comparable bioavailability, pharmacokinetics and weight loss to subcutaneous administration &#8211; &#8211; RT-116 was well tolerated with no serious adverse events &#8211; &#8211; Data adds to growing body of evidence of the RaniPill\u00ae platform\u2019s potential to enable oral delivery of multiple obesity treatments &#8211; &#8211; Phase 1 study for RT-114, an oral GLP-1\/GLP-2 dual agonist for the treatment of obesity, expected to initiate in 2025 &#8211; SAN JOSE, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) &#8212; Rani Therapeutics Holdings, Inc. (\u201cRani Therapeutics\u201d or \u201cRani\u201d) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced new pharmacokinetic and pharmacodynamic data from a preclinical study evaluating the &hellip; Continue reading &quot;Rani Therapeutics Announces Preclinical Data Demonstrating Successful Oral Delivery of Semaglutide via RaniPill\u00ae HC&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/rani-therapeutics-announces-preclinical-data-demonstrating-successful-oral-delivery-of-semaglutide-via-ranipill-hc\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-05T21:20:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1MzgyMCM2NzM3NjQ3IzIyMDg2OTk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rani-therapeutics-announces-preclinical-data-demonstrating-successful-oral-delivery-of-semaglutide-via-ranipill-hc\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rani-therapeutics-announces-preclinical-data-demonstrating-successful-oral-delivery-of-semaglutide-via-ranipill-hc\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Rani Therapeutics Announces Preclinical Data Demonstrating Successful Oral Delivery of Semaglutide via RaniPill\u00ae HC\",\"datePublished\":\"2025-02-05T21:20:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rani-therapeutics-announces-preclinical-data-demonstrating-successful-oral-delivery-of-semaglutide-via-ranipill-hc\\\/\"},\"wordCount\":1262,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rani-therapeutics-announces-preclinical-data-demonstrating-successful-oral-delivery-of-semaglutide-via-ranipill-hc\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1MzgyMCM2NzM3NjQ3IzIyMDg2OTk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rani-therapeutics-announces-preclinical-data-demonstrating-successful-oral-delivery-of-semaglutide-via-ranipill-hc\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rani-therapeutics-announces-preclinical-data-demonstrating-successful-oral-delivery-of-semaglutide-via-ranipill-hc\\\/\",\"name\":\"Rani Therapeutics Announces Preclinical Data Demonstrating Successful Oral Delivery of Semaglutide via RaniPill\u00ae HC - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rani-therapeutics-announces-preclinical-data-demonstrating-successful-oral-delivery-of-semaglutide-via-ranipill-hc\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rani-therapeutics-announces-preclinical-data-demonstrating-successful-oral-delivery-of-semaglutide-via-ranipill-hc\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1MzgyMCM2NzM3NjQ3IzIyMDg2OTk=\",\"datePublished\":\"2025-02-05T21:20:32+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rani-therapeutics-announces-preclinical-data-demonstrating-successful-oral-delivery-of-semaglutide-via-ranipill-hc\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rani-therapeutics-announces-preclinical-data-demonstrating-successful-oral-delivery-of-semaglutide-via-ranipill-hc\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rani-therapeutics-announces-preclinical-data-demonstrating-successful-oral-delivery-of-semaglutide-via-ranipill-hc\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1MzgyMCM2NzM3NjQ3IzIyMDg2OTk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1MzgyMCM2NzM3NjQ3IzIyMDg2OTk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rani-therapeutics-announces-preclinical-data-demonstrating-successful-oral-delivery-of-semaglutide-via-ranipill-hc\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Rani Therapeutics Announces Preclinical Data Demonstrating Successful Oral Delivery of Semaglutide via RaniPill\u00ae HC\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Rani Therapeutics Announces Preclinical Data Demonstrating Successful Oral Delivery of Semaglutide via RaniPill\u00ae HC - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/rani-therapeutics-announces-preclinical-data-demonstrating-successful-oral-delivery-of-semaglutide-via-ranipill-hc\/","og_locale":"en_US","og_type":"article","og_title":"Rani Therapeutics Announces Preclinical Data Demonstrating Successful Oral Delivery of Semaglutide via RaniPill\u00ae HC - Market Newsdesk","og_description":"&#8211; Oral semaglutide administered via the RaniPill\u00ae HC (RT-116) demonstrated comparable bioavailability, pharmacokinetics and weight loss to subcutaneous administration &#8211; &#8211; RT-116 was well tolerated with no serious adverse events &#8211; &#8211; Data adds to growing body of evidence of the RaniPill\u00ae platform\u2019s potential to enable oral delivery of multiple obesity treatments &#8211; &#8211; Phase 1 study for RT-114, an oral GLP-1\/GLP-2 dual agonist for the treatment of obesity, expected to initiate in 2025 &#8211; SAN JOSE, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) &#8212; Rani Therapeutics Holdings, Inc. (\u201cRani Therapeutics\u201d or \u201cRani\u201d) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced new pharmacokinetic and pharmacodynamic data from a preclinical study evaluating the &hellip; Continue reading \"Rani Therapeutics Announces Preclinical Data Demonstrating Successful Oral Delivery of Semaglutide via RaniPill\u00ae HC\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/rani-therapeutics-announces-preclinical-data-demonstrating-successful-oral-delivery-of-semaglutide-via-ranipill-hc\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-05T21:20:32+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1MzgyMCM2NzM3NjQ3IzIyMDg2OTk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rani-therapeutics-announces-preclinical-data-demonstrating-successful-oral-delivery-of-semaglutide-via-ranipill-hc\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rani-therapeutics-announces-preclinical-data-demonstrating-successful-oral-delivery-of-semaglutide-via-ranipill-hc\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Rani Therapeutics Announces Preclinical Data Demonstrating Successful Oral Delivery of Semaglutide via RaniPill\u00ae HC","datePublished":"2025-02-05T21:20:32+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rani-therapeutics-announces-preclinical-data-demonstrating-successful-oral-delivery-of-semaglutide-via-ranipill-hc\/"},"wordCount":1262,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rani-therapeutics-announces-preclinical-data-demonstrating-successful-oral-delivery-of-semaglutide-via-ranipill-hc\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1MzgyMCM2NzM3NjQ3IzIyMDg2OTk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rani-therapeutics-announces-preclinical-data-demonstrating-successful-oral-delivery-of-semaglutide-via-ranipill-hc\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/rani-therapeutics-announces-preclinical-data-demonstrating-successful-oral-delivery-of-semaglutide-via-ranipill-hc\/","name":"Rani Therapeutics Announces Preclinical Data Demonstrating Successful Oral Delivery of Semaglutide via RaniPill\u00ae HC - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rani-therapeutics-announces-preclinical-data-demonstrating-successful-oral-delivery-of-semaglutide-via-ranipill-hc\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rani-therapeutics-announces-preclinical-data-demonstrating-successful-oral-delivery-of-semaglutide-via-ranipill-hc\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1MzgyMCM2NzM3NjQ3IzIyMDg2OTk=","datePublished":"2025-02-05T21:20:32+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rani-therapeutics-announces-preclinical-data-demonstrating-successful-oral-delivery-of-semaglutide-via-ranipill-hc\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/rani-therapeutics-announces-preclinical-data-demonstrating-successful-oral-delivery-of-semaglutide-via-ranipill-hc\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rani-therapeutics-announces-preclinical-data-demonstrating-successful-oral-delivery-of-semaglutide-via-ranipill-hc\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1MzgyMCM2NzM3NjQ3IzIyMDg2OTk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1MzgyMCM2NzM3NjQ3IzIyMDg2OTk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rani-therapeutics-announces-preclinical-data-demonstrating-successful-oral-delivery-of-semaglutide-via-ranipill-hc\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Rani Therapeutics Announces Preclinical Data Demonstrating Successful Oral Delivery of Semaglutide via RaniPill\u00ae HC"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/809369","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=809369"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/809369\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=809369"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=809369"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=809369"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}